CRIS Current Research Information System

FORNARI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.432
NA - Nord America 3.040
EU - Europa 2.317
AF - Africa 184
SA - Sud America 137
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 2
Totale 9.130
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.003
SG - Singapore 905
CN - Cina 876
VN - Vietnam 836
IT - Italia 675
GB - Regno Unito 344
HK - Hong Kong 258
DE - Germania 239
SE - Svezia 206
FR - Francia 159
IN - India 147
NL - Olanda 144
KR - Corea 104
BR - Brasile 95
RU - Federazione Russa 87
FI - Finlandia 84
IE - Irlanda 84
JP - Giappone 75
CH - Svizzera 72
UA - Ucraina 58
ZA - Sudafrica 58
BG - Bulgaria 50
CI - Costa d'Avorio 35
SC - Seychelles 35
ID - Indonesia 32
TH - Thailandia 31
PH - Filippine 28
EE - Estonia 25
TG - Togo 25
CA - Canada 23
BD - Bangladesh 21
JO - Giordania 19
AT - Austria 18
PK - Pakistan 18
PL - Polonia 18
AR - Argentina 15
EU - Europa 15
MX - Messico 13
TW - Taiwan 12
BE - Belgio 11
IQ - Iraq 11
TR - Turchia 11
HR - Croazia 10
EC - Ecuador 9
DZ - Algeria 8
ES - Italia 7
UZ - Uzbekistan 6
EG - Egitto 5
GR - Grecia 5
IL - Israele 5
LT - Lituania 5
MY - Malesia 5
PE - Perù 5
CZ - Repubblica Ceca 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
IR - Iran 3
NG - Nigeria 3
NP - Nepal 3
PY - Paraguay 3
TN - Tunisia 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
CO - Colombia 2
ET - Etiopia 2
GH - Ghana 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
OM - Oman 2
PS - Palestinian Territory 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AM - Armenia 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
DK - Danimarca 1
GE - Georgia 1
HN - Honduras 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
ML - Mali 1
MM - Myanmar 1
NC - Nuova Caledonia 1
NO - Norvegia 1
SI - Slovenia 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
Totale 9.129
Salva come PNG Salva come JPEG
Città #
Singapore 651
Ashburn 394
Southend 285
Fairfield 257
Bologna 235
Hong Kong 233
Hefei 205
Ho Chi Minh City 200
Hanoi 191
Chandler 184
San Jose 180
Woodbridge 135
Houston 121
Seattle 121
Santa Clara 119
Wilmington 111
Beijing 104
Ann Arbor 95
Seoul 92
Dublin 84
Boardman 82
Council Bluffs 79
Princeton 78
Dallas 73
Helsinki 73
Bern 68
Lauterbourg 68
Los Angeles 65
Cambridge 64
Tokyo 57
Sofia 50
Da Nang 45
Milan 41
Abidjan 35
Dong Ket 35
New York 34
Jacksonville 30
Johannesburg 30
Nanjing 30
Haiphong 29
Padova 29
Amsterdam 27
Westminster 27
Redondo Beach 26
Lomé 25
San Diego 25
Florence 23
Buffalo 22
Munich 22
Frankfurt am Main 21
Jinan 21
Jakarta 20
Amman 19
Bengaluru 18
Berlin 18
Guangzhou 17
São Paulo 16
Chicago 15
Nanchang 15
Saint Petersburg 15
Hebei 14
Orem 14
Turin 14
Warsaw 14
Bangkok 13
London 13
Verona 12
Vienna 12
Zhengzhou 12
Brussels 11
Hải Dương 11
Nuremberg 11
Changsha 10
Düsseldorf 10
Modena 10
Montreal 10
Phoenix 10
Pune 10
San Giorgio di Piano 10
Shenyang 10
Shenzhen 10
Hangzhou 9
Lahore 9
Mülheim 9
Parma 9
Rome 9
Shanghai 9
Can Tho 8
Chennai 8
Des Moines 8
Falls Church 8
Forlì 8
Lappeenranta 8
Paris 8
Taizhou 8
Tianjin 8
Toronto 8
Wuhan 8
Xi'an 8
Bremen 7
Totale 5.882
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 277
Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies 264
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 257
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate 245
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 230
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 226
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 223
LncRNAs as novel players in hepatocellular carcinoma recurrence 221
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 211
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 200
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 185
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 185
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 185
CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. 184
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 180
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma 179
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 176
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 174
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 172
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 172
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 170
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 169
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 166
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 164
TP53/MicroRNA interplay in hepatocellular carcinoma 164
Oncogenic role of miR-483-3p at the IGF2/483 locus. 161
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 161
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 158
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 153
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 152
Design, Synthesis and Biological Evaluation of Pyrazole derivatives as Potential multikinase Inhibitors in Hepatocarcinoma. 152
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model 152
MicroRNAs in Animal Models of HCC 149
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 144
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 143
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing? 141
Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate 140
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 138
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 136
MicroRNA involvement in hepatocellular carcinoma. 134
The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1 alpha Activity by Changing miR Expression Patterns in Human Cancer Cells 130
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 127
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 118
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 109
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 108
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 107
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming 102
null 101
Mir-30e-3p/CXCL3 axis is involved in sorafenib resistance of hepatocellular carcinoma through the modulation of the tumor immune microenvironment 91
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 77
Animal models of hepatocellular carcinoma prevention 75
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 70
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 66
Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus 65
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC 62
MicroRNA and hepatocellular carcinoma: biology and prognostic significance 61
Towards precision medicine: a preliminary collection of patient-derived organoids for the screening of personalised therapies in hepatocellular carcinoma 59
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 59
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 58
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated HCC patients. 57
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic cencerogenesis 57
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 54
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 53
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 51
CXCL3 is a target of miR-30e-3p and predicts tumor escape in sorafenib-treated HCC patients. 51
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 50
MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts tumour escape to sorafenib Treatment 45
MiR-22-3p targets the G2/M checkpoint inhibitor Wee1 and represents a possible biomarker of TACE response in hepatocellular carcinoma 37
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 36
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma 34
Totale 9.363
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.378
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.378
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021161 0 0 0 0 0 0 0 0 0 39 23 99
2021/2022853 45 20 44 75 60 39 12 120 28 82 215 113
2022/2023936 90 95 56 103 52 78 23 55 164 27 72 121
2023/2024375 40 51 12 47 41 80 8 17 12 27 13 27
2024/20251.506 79 211 126 101 159 48 110 36 37 168 111 320
2025/20263.968 370 378 335 263 350 293 521 219 974 265 0 0
Totale 9.363